FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	quizartinib Resistant: C4 – Case Studies quizartinib Resistant : C4	quizartinib Resistant: C4 – Case Studies quizartinib Resistant : C4

FLT3-ITD mutation + FLT3-TKD mutation

Associations